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Abstract
Congenital hyperinsulinism of infancy (CHI) is a rare disorder characterized by severe hypoglycemia due to inappropriate
insulin secretion. The genetic causes of CHI have been found in genes regulating insulin secretion from pancreatic b-cells;
recessive inactivating mutations in the ABCC8 and KCNJ11 genes represent the most common events. Despite the advances
in understanding the molecular pathogenesis of CHI, specific genetic determinants in about 50 % of the CHI patients remain
unknown, suggesting additional locus heterogeneity. In order to search for novel loci contributing to the pathogenesis of
CHI, we combined a family-based association study, using the transmission disequilibrium test on 17 CHI patients lacking
mutations in ABCC8/KCNJ11, with a whole-exome sequencing analysis performed on 10 probands. This strategy allowed the
identification of the potential causative mutations in genes implicated in the regulation of insulin secretion such as
transmembrane proteins (CACNA1A, KCNH6, KCNJ10, NOTCH2, RYR3, SCN8A, TRPV3, TRPC5), cytosolic (ACACB, CAMK2D,
CDKAL1, GNAS, NOS2, PDE4C, PIK3R3) and mitochondrial enzymes (PC, SLC24A6), and in four genes (CSMD1, SLC37A3, SULF1,
TLL1) suggested by TDT family-based association study. Moreover, the exome-sequencing approach resulted to be an
efficient diagnostic tool for CHI, allowing the identification of mutations in three causative CHI genes (ABCC8, GLUD1, and
HNF1A) in four out of 10 patients. Overall, the present study should be considered as a starting point to design further
investigations: our results might indeed contribute to meta-analysis studies, aimed at the identification/confirmation of
novel causative or modifier genes.
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Introduction
Congenital hyperinsulinism (CHI), previously known as persis-
tent hyperinsulinemic hypoglycemia of infancy (PHHI,
MIM256450), is characterized by severe hypoglycemia due to
inappropriate insulin secretion from pancreatic b-cells. If improp-
erly managed, hypoglycemia can cause brain damage, learning
disability, and even death [1]. This condition affects at least 1/
50,000 children of European descent, and it has been reported in
nearly all major ethnic groups [2].
Histologically, CHI can be associated either with diffuse insulin
secretion or with focal adenomatous hyperplasia. These two forms
share a similar clinical presentation, but result from different
molecular mechanisms. Recently, a positron emission tomography
scan using Fluorine-18 L-3,4-dihydroxyphenylalanine (18-fluoro
DOPA-TC-PET-scan) has been used to distinguish focal from
diffuse forms. Diffuse CHI (Di-CHI) is characterized by autosomal
recessive or (less frequently) dominant inheritance, whereas focal
CHI (Fo-CHI) is due to a germline paternal mutation (in the
ABCC8 or KCNJ11 gene) in addition to a somatic loss of the
maternally-derived chromosome 11p15.1 region in pancreatic b-
cells [2]. According to the molecular defects, CHI has been
classified as a channelopathy (KATP channel), as a metabolic
enzyme/transporter anomaly, or as a transcription factor defect
[1]. Medical treatments of CHI include different drugs such as oral
diazoxide (channel activator), somatostatin analogue (octreotide)
injections, and appropriate diet. The surgical treatment with
subtotal pancreatectomy is required in Di-CHI when medical
treatment and dietary therapies are ineffective, whereas Fo-CHI
can be cured with resection of the focal area of adenomatous
hyperplasia. In the first case, the long-term outcome is character-
ized by the risk of developing diabetes.
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Overall, CHI causative mutations have been documented in 10
genes, allowing a molecular diagnosis for nearly 50% of CHI
patients [3,4]. The most common molecular cause of CHI is the
dysfunction of the pancreatic K+ATP channel encoded by the
sulfonylurea receptor gene (SUR1, alias ABCC8) and the inward-
rectifying potassium channel gene (KIR6.2, alias KCNJ11). Less
frequently, recessive mutations in the HADH gene (3-hydroxyacyl-
Coenzyme A dehydrogenase) have been reported. Dominant
forms of CHI are due to either activating mutations in
mitochondrial matrix enzymes, GLUD1 (glutamate dehydrogenase
1) and UCP2 (mitochondrial uncoupling protein 2), or to
mutations in HNF4A (hepatocyte nuclear factor 4 alpha) and
SLC16A1 (monocarboxylate transporter 1). Activating mutations in
the GCK (glucokinase) may also lead to CHI, and an autosomal
dominant mutation in INSR (insulin receptor gene) has been
described in a large Danish pedigree [5]. Very recently, mutations
in the HNF1A (hepatocyte nuclear factor 1 alpha) gene have been
reported in CHI patients [6,7].
Insulin secretion is regulated by a complex network of proteins
[8] acting at the cellular membrane level (i.e. ATP sensitive K+
channels, Ca2+, Na+ voltage-gated channels, glucose transporters,
and transient receptors) [9], at the intracellular level (i.e.
endoplasmic reticulum ion channels), and at the mitochondrial
level (i.e. enzymes) [10]. Since CHI is characterized by severe
hypoglycemia due to inappropriate insulin secretion from pancre-
atic b-cells, we hypothesized that mutations in genes involved in
this process might be responsible for the disease. Moreover,
considering the phenotypic variability observed within CHI
families, ‘‘phenotypic modifier’’ genes might contribute to the
global genetic picture of this disorder as described for other
Mendelian disorders [11].
The mutational screening of CHI causative genes is usually
carried out by PCR amplifications and direct Sanger sequencing,
using an iterative approach based on clinical features and/or on
medical treatment response [2].
High-density single nucleotide polymorphism (SNP)-array
technology has been widely used to perform linkage analysis,
including the transmission-disequilibrium test (TDT). Moreover,
the combination of linkage analysis with haplotype information
(applied to trios) has been successful applied to map Mendelian
traits [12] and has led to the identification of gene variants causing
diseases and birth defects [13]. Recent developments in high-
throughput sequence capture methods and next-generation
sequencing (NGS) approaches have made feasible the analysis of
the whole human exome. The exome deep sequencing, called
whole-exome sequencing (WES) analysis, has already provided the
opportunity to detect causal gene variants in dominant and
recessive disorders [14,15] and it has been recently proposed as a
powerful tool to improve the molecular diagnostic of neonatal
diabetes and maturity onset diabetes of the young (MODY)
[16,17].
Here, we applied a multi-step screening strategy aimed at
identifying genes putatively related to CHI. This strategy included
a TDT study on 17 patients and their families and exome
sequencing in 10 CHI probands. We have also evaluated if NGS is
a suitable alternative diagnostic approach to classical Sanger
sequencing for CHI.
Results and Discussion
To highlight novel CHI-associated genetic loci, we performed a
multi-step screening strategy (Figure S1). First we carried out a
genetic screening of ABCC8/KCNJ11 genes on 33 CHI probands
by classic sequencing approach; then, applying a genome wide
SNP genotyping analysis on 17 non-consanguineous CHI patients
(lacking ABCC8/KCNJ11 mutations) and their families, we
performed a TDT family-based association study, and finally we
applied WES on 10 selected CHI probands (five from the TDT
analysis group and five not subjected to previous molecular
screening). To prioritize the coding variants identified by WES, we
crossed the list of filtered WES variants with that comprising the
TDT associated genes (51 genes), the known CHI-causative ones
(10 genes), and a refined list of 211 CHI-functionally-related genes
(see Methods for details).
Whole-genome SNP Genotyping and TDT Analysis
The whole-genome SNP genotyping was performed on the 17
nuclear families. The overall results of the TDT association
analysis are presented in the Manhattan plot (Figure S2). We
obtained 144 SNPs associated at P#0.005 (Table S1). None of
these SNPs reached the stringent genome-wide significance of
P,4.461027; however, we considered any empirical P-value at
4.961025 as ‘‘suggestive’’ (i.e. a potential reflection of an
association signal) [18]. After genome annotation, we found that
a subset of these SNPs map within/close to 51 genes (Table S1).
Interestingly, we identified two SNPs located in the region of the
TLL1 (tolloid-like1) gene: rs3775321 (P = 0.000049; OR=7.3,
95%CI=2.2–24.5) and rs4691229 (P= 0.00043; OR=0.2,
95%CI=0.1–0.5). Using haplotype analysis we were able to
confirm and to refine the potential association of the TTL1 locus to
the CHI (Table S2).
Applying the copy-number and homozygosity mapping analyses
on 17 probands, we confirmed the absence of deletion or
amplification events (data not shown); conversely, in two probands
we found runs of homozygosity (ROH) longer than 2 Mb. The
ROH segments were located on chromosome 4q24 (4.2 Mb
containing 14 genes) in patient HI06, and on chromosome
6p36.33-q13.33 (7 Mb containing 26 genes) in patient HI18. By
the subsequent WES analysis, we verified that all genes located in
ROH segments were lacking mutations.
WES Analysis and Gene Variants Identification
WES was performed on 10 CHI probands (Table 1). By
sequencing the exome DNA libraries, we obtained 2.8–5.4 Gb of
mapped sequence achieving a mean depth of target coverage
between 27 and 506, and an average of 19,181 variations per
patient, including substitutions and indels (Table 2). Overall, the
results of the percentage of target coverage at 106 were fairly
homogeneous among samples (ranging from 83.5 to 88.7%). By
looking to CHI known causative genes, we obtained at least 106
coverage in .95% of coding regions for HADH, SLC16A1, UCP2,
GLUD1, and KCNJ11, whereas the values were slightly less
uniform, reaching 90, 83, 80, and 75% for INSR, ABCC8, GCK,
HNF4A, respectively. Only for HNF1A the percentage was low
(55%). By focusing on non-synonymous single nucleotide variants
(SNV, missense and nonsense) we counted an average of 9,395
variants per patient. After the filtering procedure, we counted an
average of 430 variants (ranging from 368 to 494) that were not
reported in publicly accessible databases (dbSNP132, 1000Ge-
nomes Project) and in our in-house database (built on 15 sequenced
exomes, Italian individuals).
To prioritize the list of SNV obtained by WES, we used a list of
271 candidate genes based on three functional criteria of inclusion:
the TDT associated genes (51 genes; Table S1), the known
causative genes (10 genes), and 210 functionally-related genes
(Table S3). Using this candidate gene list, we identified an average
of 4.2 variants per patient which were then analyzed for their
predicted impact on the encoded protein by predictor tools
Exome Sequencing in Congenital Hyperinsulinism
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resulting in a final list of 27 single base variants distributed in 24
genes (Table 3). Among them, we found 24 missense mutations
causing amino-acid changes predicted to be potentially damaging
with high confidence by at least one prediction tool; we also
identified two nonsense mutations and one splice site mutation.
The mutations have been all confirmed by direct Sanger
sequencing (data not shown).
Biological Relevance of Known and Novel CHI Gene
Variants
By WES in 10 CHI patients we were able to identify four
patients carrying mutations in three CHI causative genes (ABCC8,
GLUD1, and HNF1A), seven patients showed genetic lesions in 17
genes implicated in the regulation of insulin secretion (KCNH6,
GNAS, ACACB, NOTCH2, RYR3, TRPV3, TRPC5, CAMK2D,
PIK3R3, CDKAL1, SCN8A, KCNJ10, PDE4C, NOS2, SLC24A6,
CACNA1A, PC) and four patients carrying mutations in four genes
suggested by the TDT analysis (SLC37A3, CSMD1, SULF1, TLL1).
Overall, we identified: one patient displaying a unique variant in
one gene, two patients are displaying mutations in two genes, and
the remaining carrying multiple variants in more than two genes.
For known genes, we found a compound heterozygous patient
carrying two mutations in ABCC8: a nonsense mutation pQ953X
(CM981878) previously described [19] and a novel c.3989-2A.G
splicing variant (patient HI39) abolishing the canonical acceptor
splice site. We also identified a homozygous ABCC8 variant
(p.A390E) in exon 7 within a ROH on chromosome 11 (proband
Table 1. Clinical characteristics of the ten CHI probands.
Proband HI01P HI06P HI18P HI26P HI31P HI37P HI39P HI42P HI43P HI44P
Sex M M F F M M F M M F
Macrosomia No No No No Yes No No Yes Yes No
Consanguinity No No No No No No No Yes No No
Onset 16 m 4 m 5 m 2 d 2 d 1 y 3 d 2 d 1 y 14 m
Clinical form mild severe severe severe mild mild severe severe mild severe
Pancreatectomy No No Yes No No No No Yes No No
Histology No No Di-CHI No No No No Di-CHI No No
TC PET No Fo-CHI Di-CHI No No No Di-CHI Di-CHI No Di-CHI
Response to Diazoxide Yes* Yes No Yes Yes* Yes Yes1 No Yes Yes
Other metabolic features
Leucine sensitive No No Yes No No No No No No No
Hyperammonemia No No No No No No No No Yes No
Mental retardation No No No No No No No No Yes No
Epilepsy No No No No No No No No Yes No
SNP array analysis Yes Yes Yes Yes Yes No No No No No
*Patient in Remission.
1Medical Treatment with Diazoxide and Octreotide.
Abbreviations: m, month; d, day; y, year; Di, Diffuse; Fo Focal.
doi:10.1371/journal.pone.0068740.t001
Table 2. Exome coverage and target coverage statistics of ten CHI probands.
CHI patients HI01P HI06P HI18P HI26P HI31P HI37P HI39P HI42P HI43P HI44P
Whole exome sequencing results
Total number of raw reads (10‘6) 81.87 62.75 68.38 52.75 65.58 80.60 84.95 45.53 68.11 88.79
Total number of mapped reads (10‘6) 67.28 49.14 50.77 41.70 52.64 66.24 70.46 36.74 54.61 71.53
Target coverage (106) (%) 88.67 87.38 88.00 86.46 88.40 88.51 88.36 83.55 88.43 88.16
Target coverage (206) (%) 77.84 73.82 74.90 70.14 76.15 77.20 77.48 62.06 76.02 77.08
Mean read depth (x) 50.19 39.26 40.29 33.24 42.06 47.52 49.48 27.04 41.33 49.78
Exonic SNV variants analysis
Total exonic SNP (Nu) 19208 18751 19361 18959 19200 19697 19287 17808 20252 19293
Total exonic Indels (Nu) 281 258 262 240 265 247 257 223 266 282
Missense and Nonsense SNPs (Nu) 9436 9187 9461 9318 9456 9679 9433 8660 9890 9434
Filtering (dbSNP) 722 794 863 830 846 883 905 685 952 765
Filtering (1000g MAF,0.005) 618 705 761 721 737 778 800 608 825 652
Filtering (internal DB) 369 415 480 414 438 423 457 405 495 414
doi:10.1371/journal.pone.0068740.t002
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HI42) which has been previously reported in a case report [20].
The GLUD1 mutation (pS498L,) was found at the heterozygous
state in patient (HI43) who was affected by a mild CHI-HA
(Hyperinsulinism-Hyperammoniemia) form and epilepsy. This
mutation is associated to CHI-HA in the Human Gene Mutation
Database (CM980942). Finally, we identified a HNF1A gene
mutation (proband HI01) that has been previously reported in
MODY3 patients [21]. Interestingly, the phenotype of our patient
was similar to the one described by Stanescu, who recently
reported mutations in the HNF1A gene in two cases of CHI [22].
For novel genes, by literature mining and database queries we
have obtained indications about their biological relevance for
pancreatic b-cell (Figure S3) and by gene ontology (GO)
classification we group them in three main categories of cellular
components such as transmembrane, cytosolic and mitochondrial
proteins (Table 4).
Transmembrane proteins. The CACNA1A gene encodes
the alpha 1A subunit of the voltage-dependent (VDCC), P/Q type
calcium channel. The protein is participating in the complex
regulation of insulin secretion: the mechanism implicates that the
closure of the KATP channels stimulates insulin secretion
depolarizing the plasma membrane; the consequent opening of
VDCC results in influx of extracellular Ca2+, which then triggers
insulin exocytosis in pancreatic b-cells [23,24]. CSMD1 gene
(belonging to the TDT analysis list) encodes an integral membrane
protein with unknown molecular function. The KCNH6 (alias
HERG2) gene encodes a voltage-gated K+ channel (KV) belonging
to the 6-TM family of potassium channels; interestingly; it has
been described that HERG channels have a crucial role in
regulating insulin secretion, raising the possibility that HERG
mutations might be involved in some hyperinsulinemic diseases of
unknown origin [25]. The KCNJ10 gene encodes a member of the
inward-rectifier potassium channel family (also known as 2-TM
channels) and its mutations have been associated to SeSAME
syndromes [26]. The NOTCH2 gene encodes a type 1 transmem-
brane receptor that is expressed in the ductal cells during
pancreatic organogenesis [27], and is belonging to the Notch
family that has been suggested to have a role in diabetes [28].
Recently, a NOTCH2 variant has been reported in one MODY
affected patient [16], therefore similarly to other MODY causative
genes [29–31], that are resulted also CHI causative, we propose
NOTCH2 as a good candidate for further investigations. The RYR3
Table 3. Whole-exome sequencing identification of non-synonymous SNP variants of 10 CHI patients.
Sample ID Gene symbol Chr Position RefSeq ID Amino Acid change PolyPhen/SIFT prediction
HI01 HNF1A chr12 121426790 NM_000545 p.A161T* ++/++
KCNH6 chr17 61615518 NM_030779 p.V532F 2/++
HI06 GNAS chr20 57428464 NM_080425 p.E48D +/++
ACACB chr12 109683531 NM_001093 p.N1760S 2/++
NOTCH2 chr1 120464961 NM_024408 p.R1704H +/++
HI18 SLC37A3 chr7 140035229 NM_032295 p.S389L 2/++
CSMD1 chr8 3889535 NM_033225 p.R168W +/++
RYR3 chr15 33938601 NM_001036 p.T1272M +/++
HI26 TRPV3 chr17 3417258 NM_145068 p.L776F ++/++
TRPC5 chrX 111020098 NM_012471 p.G789R 2/++
CAMK2D chr4 114435066 NM_172115 p.R275C ++/++
HI31 PIK3R3 chr1 46521492 NM_003629 p.R306X Nonsense
CDKAL1 chr6 21231212 NM_017774 p.S561F 2/++
SCN8A chr12 52163721 NM_014191 p.V1148M 2/++
KCNJ10 chr1 160011280 NM_002241 p.R348H 2/++
HI37 PDE4C chr19 18331081 NM_000923 p.R253C ++/++
HI39 ABCC8 chr11 17428964 NM_000352 p.Q953X* Nonsense
ABCC8 chr11 17418595 NM_000352 Splice site
NOS2 chr17 26107857 NM_000625 p.R314C ++/++
HI42 ABCC8 chr11 17474673 NM_000352 p.A390E 2/++
SLC24A6 chr12 113737647 NM_024959 p.Y564H ++/++
SULF1 chr8 70501306 NM_015170 p.A222T 2/++
HI43 GLUD1 chr10 88817449 NM_005271 p.S498L* 2/2
TLL1 chr4 166981332 NM_012464 p.G667S ++/2
HI44 CACNA1A chr19 13325090 NM_001127222 p.R1966Q ++/++
PC chr11 66619274 NM_001040716 p.N657Y ++/++
TLL1 chr4 166986893 NM_012464 p.H689P ++/++
*Mutation reported in Human Genome Mutation Database( HGMD).
PolyPhen/SIFT: (2) benign or tolerated; (+) possibly damaging/DAMAGING Low confidence;
(++) probably damaging/DAMAGING.
In bold known causative genes.
doi:10.1371/journal.pone.0068740.t003
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gene encodes for receptors that are intracellular ion channels
expressed in human pancreatic b-cell. Interestingly, the activation
of these receptors by ryanodine stimulates the insulin secretion at
low glucose concentrations [32]. The SLC37A3 gene (belonging to
the TDT analysis list) encodes a transmembrane sugar transport-
ers family, SLC37; to date, only the SLC37A4 gene has been found
mutated in the glycogen storage disease non-1A type [33]. The
SCN8A gene encodes a member of the sodium channel alpha
subunit gene family (Nav 1.6), and it forms the ion pore region of
the voltage-gated sodium channel and mediates the voltage-
dependent sodium ion permeability of excitable membranes. Nav
1.6 together with Nav 1.7 (the other a subunit of human b-cells) is
highly expressed in human islets [8,34]. The TRPV3 and TRPC5
genes encode proteins belonging to the transient receptor potential
(TRP) cation channels group, they provide the background
membrane conductance required for b-cells to depolarize upon
KATP channel closure [9], but their role in human pancreas islets
has not been studied.
Cytosolic proteins. The ACACB gene encodes a complex
multifunctional enzyme system that catalyzes the carboxylation of
acetyl-CoA to malonyl-CoA (the rate-limiting step in fatty acid
synthesis); the malonyl-CoA can act as a coupling factor that
regulates insulin secretion [35]. Interestingly, b-cell islets produce
high quantity of ACACB enzyme [36]. The CAMK2D, encodes a
protein Ca2+ sensing serine/threonine kinases (CaMK2) that it is
involved in the regulation of Ca2+ mediated glucose-sensitivity of
b-cells; in particular CaMK2 delta play a role as a feedback sensor,
linking Ca2+ induced exocytosis to the re-synthesis of insulin acting
on transcriptional regulation of genes related to the metabolic
control of insulin secretion [37]. In humans, the CaMK2 beta and
delta subtypes represent the major isoforms that are highly
expressed in b-cells [38]. The CDKAL1 gene, encodes a
methylthiotransferase that modifies tRNA to enhance the trans-
lational fidelity of proinsulin transcript [39]. Moreover, a study
using knockout mice for the CDKAL1 gene revealed its possible
role in controlling the first phase of insulin exocytosis in b-cells,
through the KATP channel responsiveness [40]. The GNAS gene
encodes the Gsa subunit of the G protein that is ubiquitously
expressed. The encoded protein stimulates adenylyl cyclase (AC),
thereby generating the second messenger cAMP. It has been
shown that mice with b-cell-specific Gsa deficiency develop severe
defect in b-cell proliferation and early onset insulin deficient
diabetes [41]. The GNAS locus has a highly complex imprinted
expression pattern and encodes four main transcripts: Gs-alpha,
XLas, NESP55, and the A/B transcript. Specifically, we found
that our mutation is referred to the XLas transcript, whose
promoter is methylated on the maternal allele and transcription-
ally active only on the paternal allele [42]. Therefore, for our
proband, we hypothesize that a post-zygotic somatic event (such as
methylation) and imprinting defect, resulting in the absence of
Table 4. Functional annotation of novel variants.
GO cellular component Relevant pathways ( KEGG) Biological process in pancreas [ref]
Transmembrane proteins
CACNA1A Calcium signaling pathway, Type II diabetes
mellitus
insulin exocytosis [23,24]
CSMD1 undetermined unknown
KCNH6 undetermined regulating insulin secretion [25]
KCNJ10 Gastric acid secretion unknown
NOTCH2 Notch signaling pathway role in diabetes, MODY [16,28]
RYR3 Calcium signaling pathway, insulin secretion [32]
SCN8A undetermined ion permeability, insulin secretion [8,34]
SLC37A3 undetermined unknown
TRPC5,TRPV3 undetermined ion permeability [9]
Cytosolic proteins
ACACB Fatty acid biosynthesis, Metabolic pathways,
Insulin signaling pathway
insulin secretion [35,36]
CAMK2D Calcium signaling pathway,Wnt signaling
pathway
insulin gene expression regulation [37]
CDKAL1 undetermined insulin gene expression, insulin exocytosis [39]
GNAS Calcium signaling pathway b-cell proliferation, diabetes [41]
NOS2 Metabolic pathways, Calcium signaling pathway b-cell proliferation, diabetes [43]
PDE4C Purine metabolism insulin secretion [45]
PIK3R3 Insulin signaling pathway, Type II diabetes
mellitus
insulin signaling [47]
SULF1 undetermined unknown
TLL1 undetermined glucose regulation [49]
Mitochondrial proteins
PC Citrate cycle (TCA cycle), Pyruvate metabolism,
Metabolic pathways
insulin secretion [10]
SLC24A6 undetermined calcium homeostasis [51]
doi:10.1371/journal.pone.0068740.t004
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expression of the maternal Gs-alpha isoform, might lead to the
expression of mutated paternal allele in some affected focal area of
the pancreas. The NOS2 gene, has been implicated in b-cell
damage and death in both type 1 and type 2 diabetes [43];
moreover, it mediates the IRS-2 expression contributing to b-cell
failure [44]. The PDE4C gene encodes a protein belonging to the
cyclic nucleotide phosphodiesterase subfamily PDE4. This protein
hydrolyzes the second messenger, cAMP, thus playing a key role in
many important physiological processes such as those mediated by
hormones and neurotransmitters. It has been demonstrated that
PDE1–4 enzymes are expressed in rodent pancreatic islets and b-
cells [45] while PDE4C is the major isoform in human islets [46].
Furthermore, it has been shown that family-selective inhibition of
PDE (PDE1, PDE3 and to some extent also PDE4) potentiates
glucose-stimulated insulin secretion (GSIS); in particular, siRNA-
mediated knockdown of PDE4C significantly enhanced GSIS in
rat INS-1 (832/13) cells [45]. The PIK3R3 encodes a family of
lipid kinases that binds to activated (phosphorylated) protein-
tyrosine kinases through the SH2 domain, regulates their kinase
activity and triggers a plethora of intracellular events involving also
the insulin signaling [47]. Notably, we found a mutation in the
exon 7 that causes the complete loss of the second SH2 domain
that may be deleterious to the protein function (Table 3). The
SULF1 gene (belonging to the TDT analysis list) encodes an
enzyme with arylsulphatase activity acting on cell-surface heparan
sulphate proteoglycans. It has been suggested an important role of
this enzyme in pancreatic cancer progression [48]. The TLL1 gene
(belonging to the TDT analysis list) encodes an astacin-like zinc-
dependent metalloprotease and is a subfamily member of the
metzincin family; interestingly, it has been described as a gene
responsive to a member of the NR4A subgroup of nuclear
receptors that have been implicated in the regulation of glucose
and lipid metabolism in insulin-sensitive tissues [49].
Mitochondrial proteins. The PC gene encodes the enzyme
pyruvate carboxylase, which is a mitochondrial enzyme involved
in gluconeogenesis, lipogenesis, insulin secretion, and synthesis of
the neurotransmitter glutamate. PC seems to play an important
role in the ‘‘amplifying signal’’ responsible for insulin secretion
trough the KATP independent pathway [10]. Interestingly, Pineda
et al. [50] reported an infant with what they termed the ‘‘French’’
type of pyruvate carboxylase deficiency, presenting initial neonatal
symptoms such as respiratory distress, severe metabolic acidosis,
and a tendency to hypoglycaemia. The SLC24A6 gene encodes a
mitochondrial Na+/Ca2+ exchanger (NCKX6) that maintain
cellular calcium homeostasis and it plays a critical role in the
mitochondrial Ca2+ transport in skeletal muscle, stomach, and
pancreas [51].
Conclusions
In the present investigation, we demonstrated that exome
sequencing is useful as a diagnostic tool for CHI because identifies
mutations in known genes but also gives the opportunity to
discover potential damaging mutations affecting several genes
combined in a complex fashion. WES, associated with family-
based association analysis, revealed that CHI patients, lacking
mutation in known causative genes, carry multiple exonic
mutations. Due to the small number of patients of this study,
some cautions should be taken into account to interpret the
pathological role of identified variants. However, due to difficulties
to collect large samples for such a rare disease, our results may be
useful for future meta-analyses that will combine genetic data
provided by other individual studies. The present study should be
regarded as a starting point to design further investigations aimed
from one side to the molecular characterization of the identified
mutations, and from the other to investigate possible modifier
genes, which might be relevant for the CHI pathogenesis.
Increasing the number of well-characterized clinical CHI patients
will allow the evaluation of the mutation frequency of novel gene
variants and the identification of a clearer genotype-phenotype
correlation.
Finally, we indicate that exome sequencing should be consid-
ered a valuable, time- and cost-effective diagnostic tool providing a
fine molecular classification of CHI patient in alternative to
Sanger sequencing, offering also the opportunity to better
understand the genetic basis of CHI.
Materials and Methods
Study Sample and Strategy
The study was approved by the Ethical Committee of the San
Raffaele Scientific Institute and performed according to the
principles of the Declaration of Helsinki. Written informed
consent was obtained from the next of kin on the behalf of the
minors/children participants involved in this study. A detailed
description of the study design is available through the Italian
Registry of Congenital Hyperinsulinism (http://www.progettorici.
it).
The diagnosis of CHI was carried out according to the following
criteria: a fasting and post-prandial hypoglycemia with unsup-
pressed insulin secretion, a positive response to the administration
of glucagon, negative ketone bodies in urine and plasma, and a
prolonged dependence to treatment to prevent hypoglycemia.
From the study we excluded infants from diabetic mothers,
children with transient neonatal hyperinsulinism, with insulinoma,
or Beckwith-Wiedemann Syndrome. Patients were considered to
be diazoxide responsive if satisfactory glycemic control was
achieved with doses of oral diazoxide not exceeding 20 mg/kg
per day and were considered to be in remission if good glycemic
control was maintain without further medical or surgical therapy.
Patients were considered to be unresponsive to medical treatment
if recurrent hypoglycemia episodes (,3 mmol/L) occurred during
diet treatment (milk enriched with malto-dextrine or continuous
enteral feeding) and treatment with diazoxide and octreotide at
maximum dosage.
The study design is shown in Figure S1. We enrolled a total of
38 probands and their families; 33 probands were subjected to
mutational screening of two ‘‘major’’ CHI genes (ABCC8, KCNJ11)
by Sanger sequencing, following the procedure previously
described [52]. After the mutational screening, 17 non consan-
guineous probands remained without a genetic diagnosis: together
with their parents, they were hence processed for SNP genotyping
and family-based TDT association analysis. Finally, we used WES
analysis in 10 probands (for five of them, no mutational pre-
screening was performed), either to find novel causative gene
mutations or to evaluate WES as an alternative approach to
classical Sanger sequencing. The clinical features of these patients
are reported in Table 1.
Whole-genome SNP Genotyping and Linkage Analysis
The whole-genome scan was performed by the Affymetrix
GeneChip Human Mapping 250 K NspI Array Set (Affymetrix,
Santa Clara, CA, USA), using standard protocols as described in
the GeneChipH Mapping 500 K Assay Manual. Genotypes were
called from cell intensity data by the BRLMM (Bayesian Robust
Linear Model with Mahalanobis distance) algorithm implemented
in the GeneChip Analysis Software v.4.0 (Affymetrix) using default
parameter settings. SNP array raw data are available on Array
Express repository (E-TABM-861). Copy number analysis and
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homozygosity mapping was carried out using CNAG 3.3, as
previously described [53]. Allele and genotype frequencies were
calculated for each locus and tested for Hardy-Weinberg equilib-
rium (HWE) considering only parents. For SNP quality control
(QC), we employed predetermined QC inclusion criteria [minor
allele frequency (MAF).1%, SNP call rate .90%, HWE
P.0.01]. The QC procedure also included a check for Mendelian
errors (predetermined threshold: 1%), as well as sex and pedigree
check. All procedures were performed by using the PLINK
software [54], obtaining a set of 221,605 high-performing SNP
markers for further analysis. A subset of SNPs that are in
approximate linkage equilibrium with each other were hence
selected by linkage disequilibrium (LD)-based pruning: 112,740
SNPs remained for family-based TDT association analysis.
We proceeded further performing the TDT association analysis
on the 17 trios to search for association signals highlighting novel
CHI candidate/modifier genes. Adjusted P-values were assessed
by gene-dropping permutation, flipping the allele transmitted from
parent to affected offspring, and using the default mode with the
adaptative permutation approach. The maximum number of
permutations per SNPs was 1,000,000. Considering the number of
tests conducted, any empirical P-value at 4.461027 would have
been considered significant [55]; however, none of the SNPs
reached the genome-wide significance. Hence, considering that: 1)
the study cohort is obviously underpowered by its size; 2)
‘‘suggestive’’ P-values still may reflect evidence for association;
and that 3) it is possible to make use of these suggestive P-values
through the incorporation of prior biological knowledge; we
decided to adopt P= 4.961025 as significance threshold to build a
SNP list to be used in all the subsequent analyses. All P-values are
hence presented as not corrected.
Finally, we refined the association analysis on the TLL1 gene
performing a haplotype analysis. It was performed using all SNPs
mapping in the TLL1 genomic region and the sliding window
specification option of the PLINK program (width of the window:
5 SNPs; shifting: 1 SNP at a time).
WES Analysis
Three micrograms of genomic DNA was fragmented using the
Covaris shearing system (Covaris inc., MA, USA). Exome capture
was performed with the SureSelect Human All Exon Kit (v3,
target size 50 Mb) according to the manufacturer’s instructions
(Agilent technologies, Santa Clara, CA, USA). The platform
design covers 1.22% of human genomic regions corresponding to
the NCBI Consensus CDS Database (CCDS), including more
than 700 human miRNAs from the Sanger v13 database and more
than 300 additional human non-coding RNAs in a single tube.
The selected coding regions were then massively sequenced by the
Illumina GAIIx technology (Illumina, San Diego, CA, USA);
following proprietary reversible terminator-based method and
producing 2676 bp read lengths. The paired-end sequence reads
were mapped to the reference genome (UCSC NCBI37/hg19)
using the Burrows-Wheeler Aligner (BWA) software [56] and the
variant calling was performed using SAMtools [57]. The entire
dataset of mapped reads (.bam files) is available on Sequence Read
Archive, accession number ERP002635. The detected variations
in each sample were filtered out using the minimum Phred SNP
quality score of 100, the minimum depth of 10 reads, and the
minor allele with an allelic fraction. 0.25. The variants were then
annotated by the ANNOVAR software (http://www.
openbioinformatics.org/annovar/annovar_db.html), for filtering
common variants reported in dbSNP132 (http://www.ncbi.nlm.
nih.gov), in 1000 Genomes Project (http://www.1000genomes.
org/), and in-house database.
Selection of Gene of Interest and Validation
For a focused evaluation of the whole-exome data, a list of 272
genes arising from three functional criteria of inclusion was used:
ten genes known to be causative for CHI (ABCC8, KCNJ11,
GLUD1, GCK, HADH, HFN4A, SLC16A1, UCP2, INSR and
HNF1A); 51 genes suggested by TDT association analysis (Table
S1); 145 genes associated to regulation of insulin secretion
reported in the Rat Genome Database [58] and 66 genes
indicated by reviewing the literature concerning the b-cell function
and its metabolic regulation (Table S3).
To predict the effect of non-synonymous mutations on the
encoded proteins of the selected gene list, we used two different
web tools: SIFT [59] and PolyPhen v2.0 [60]. We reported non-
synonymous mutations that were predicted deleterious at least by
one predictor tool with a high score. To investigate the presence of
functional interactions among genes, including direct (physical)
and indirect (functional) associations, we used STRING, a
database of known and predicted protein interactions [61].
Computer-assisted analysis for splice-site prediction was accom-
plished using the Neural Network Promoter Prediction Tool
(NNPPT) program (http://www.fruitfly.org/seq_tools/splice.
html) and the NetGene2 (release 2.4) program (http://www.cbs.
dtu.dk/services/NetGene2).
All variants were validated by PCR amplification of exons
carrying the identified mutation (primers sequences and PCR conditions
are available on request) using genomic DNA from CHI probands.
The amplified products were purified using montage the Micro
PCR96 plates (Merck Millipore, Billerica, MA, USA) and then
directly sequenced with the forward and reverse primers
previously used for the amplification. Sequenced products were
purified using the Montage SEQ 96 Sequencing Reaction
Cleanup kit (Merck Millipore). Sequencing analysis was carried
out using the Big Dye Terminator Cycle Sequencing Ready
Reaction Kit v3.1 and an automated DNA sequencer (ABI-3100
XL Genetic Analyser; Applied Biosystems, Foster City, CA, USA).
Factura and Sequence Navigator software Packages (Applied
Biosystems) were used for mutation detection.
Supporting Information
Figure S1 Study design. The initial study sample consisted of
a total of 65 subjects, belonging to 32 CHI families. Overall 33
probands of these families were pre-screened for mutations in the
two main CHI genes (ABCC8,KCNJ11). The 17 probands non
consanguineous (lacking causal mutations in ABCC8/KCNJ11)
together with their relatives were taken forward to whole-genome
scan by the Affymetrix GeneChip Human Mapping 250 K Array.
We applied TDT and haplotype analyses to highlight possible
susceptibility/modifier CHI genes. Finally, 5 patients from the
TDT study and 5 newly-enrolled CHI patients (not pre-screened
for ABCC8/ KCNJ11 were analyzed by whole-exome sequencing
(WES).
(TIF)
Figure S2 Manhattan plot. Results of single-locus test of
association between each of the 112,740 performing SNPs and
CHI using the TDT association analysis. 112,740 single-marker
permuted results (–log10 p-values) from the TDT test are plotted
on each chromosome; red line represents P#1023 threshold, blue
line represents P#561023 threshold.
(TIF)
Figure S3 Schematic representation of insulin secretion
in b-cell and the hypothetical role of novel CHI gene. The
entry of glucose in the b-cell trough the glucose transporter
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(GLUT2) stimulates insulin secretion by metabolic amplifying
pathways producing ATP. The increase of ATP/ADP ratio leads
to the closure of KATP channels, to the depolarization of the
plasma membrane and to the subsequent activation of VDCC
promoting influx of calcium into the cell. The overall modulation
of the cytosolic free concentration [Ca2+] is essential for the
triggering pathways of the insulin secretion. The binding of
secreted insulin to its receptors (INSR), might activates the PI3K/
Akt pathway and some transcription factors controlling insulin
gene expression. Insulin exocytosis can also be influenced by
neurotransmitters and hormones. Indeed, GLP1 actives AC
leading the elevation of cAMP and the consequent PKA activation
which finally mediates insulin exocytosis; alternatively the Ach
mobilizes intracellular Ca2+ activating of IP3 receptor; then [Ca2+]
binds to CaM activating CaMK and inducing the secretory
process of insulin. Moreover, CDKAL1 is implicated in the control
of the first phase of insulin exocytosis via KATP responsiveness.
Other transmembrane ion channels might modulate electrical
activity of the cellular membrane regulating the insulin secretion
(KCN, TRP, SCN). Abbreviations: VDCC, voltage dependent
calcium channel; TRP, transient receptor potential channels;
KCN, potassium voltage-gated channel; SCN, sodium channel
voltage-gated; ER, endoplasmic reticulum; SERCA, sarco/
endoplasmic reticulum Ca2+ATPase; GIP, glucose-dependent
insulinotropic peptide; AC, adenyl cyclase; GLP1, glucagon like
peptide 1; INS, insulin; IRS1/2, Insulin receptor substrate 1/2;
PLC, phospholipase C; IP3, Inositol trisphosphate; PKC, protein
kinase C; DAG, diacylglycerol; Gs,Gi,Gq, G proteins; PKA,
Protein kinase A; PI3K, phosphatidylinositol; CaM, calmodulin;
Ach, acetylcholine; FA, fatty acid; FFA, free fatty acid. Yellow box
indicate the CHI causative genes.
(TIF)
Table S1 TDT data and associated alleles and genes.
144 SNP resulted from TDT analysis at P#0.005. OR, TDT odd
ratio; CI L95 and CI U95, lower and upper 95% confidence
interval for TDT odds ratio; Adjusted P-value, empirical p-value
by adaptive procedure; A1/A2, A1: minor allele, A2: major allele;
NP: number of permutations.
(XLS)
Table S2 Haplotype analysis of TLL1 locus.
(XLS)
Table S3 Refined gene list. The table is including 221 gene
symbols and criteria of inclusion. PMID, pubmed identification
number; RGD, rat genome database (http://rgd.mcw.edu/).
(XLS)
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